Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Therapy
Promising results presented for tubulin binding agent, ENMD-1198
December 15th, 2005
EntreMed, Inc., (ENMD), a clinical stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, announced preclinical results for its tubulin binding agent, ENMD-1198. Results for the preclinical study were presented by EntreMed scientists during a poster session at the combined American Association for Cancer Research-U.S. National Cancer Institute-European Organization for Research and Treatment of Cancer International Conference on Molecular Targets and Cancer Therapeutics held in Philadelphia, Pennsylvania. ENMD-1198, a new chemical entity based on a modified chemical structure of 2-methoxyestradiol...
Source: Women's Health Weekly (2005-12-15)
|
